Abstracts tagged "mesenchymal stem cells and tissue engineering"

Abstract Number: 77 • 2013 ACR/ARHP Annual Meeting
Human Mesenchymal Stem Cells Cultured On Collagen Scaffolds For Cartilage Tissue Engineering
Clara Sanjurjo-Rodríguez¹, Adela Helvia Martínez-Sánchez², Tamara Hermida-Gómez¹, Isaac M. Fuentes-Boquete^1,2, Francisco J. De Toro^2,3, Julia Buján⁴, Silvia Díaz-Prado^2,3 and Francisco J. Blanco², ¹Grupo de Bioingeniería Tisular y Terapia Celular (CBTTC-CHUAC). CIBER-BBN/ISCIII. Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de Coruña (CHUAC). SERGAS. Universidade de A Coruña, A Coruña, Spain, ²Osteoarticular and Aging Res. Lab. CIBER-BBN. INIBIC- University of A Coruña, A Coruña, Spain, ³INIBIC-Universidade da Coruña, A Coruña, Spain, ⁴University of Alcalá de Henares, Department of Medical Specialties, Madrid, Spain
Background/Purpose: Osteoarthritis is a degenerative disease without a treatment. Tissue Engineering could provide an alternative tool for cartilage repair. The aim of this study was…
Abstract Number: 51 • 2013 ACR/ARHP Annual Meeting
Collagen-Based Microspheres Delivering TGF-β3 For Mesenchymal STEM CELL Differentiation: An Innovative Strategy For Cartilage Engineering
Marc Mathieu¹, E Belamie², M-N Labour², Sylvain Vigier², Christian Jorgensen³ and Daniele Noel⁴, ¹INSERM U844, Montpellier, France, ²ICGM UMR 5253, MONTPELLIER, France, ³Department of therapy & Immuno-Rhumatology, Inserm U844, CHU saint-Eloi, Université Montpellier 1, CHU Lapeyronie, Montpellier, France, ⁴Inserm U844, UM1, Montpellier, France
Background/Purpose: Because of a poor self-healing ability, joint cartilage undergoes progressive degradation in the course of aging or following traumatic injuries. One promising therapeutic approach…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].